Gerresheimer generated revenues of EUR 363 million in the second quarter of 2020, marking 4.6 per cent organic growth in the core business compared to the same quarter of the prior year.
The CEOs of Gerresheimer, Stevanato Group, and SCHOTT are committed to ensuring ample supply of pharmaceutical containers for any Covid-19 vaccine and treatment that is developed.